

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

THE GROUP'S PRODUCT CEFUROXIME SODIUM FOR INJECTION PASSED THE CONSISTENCY EVALUATION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that Cefuroxime Sodium for Injection (specifications: 0.75g; 1.5g) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, with the approval of China National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs ("Consistency Evaluation") on 12 November 2024.

Cefuroxime Sodium for Injection is a cephalosporin antibiotic, clinically applicable to the treatment of infections caused by multiple specific microbial sensitive strains, including respiratory tract infections, ear, nose, and throat infections, urinary tract infections, skin and soft tissue infections, sepsis, meningitis, gonorrhoea, bone and joint infections, puerperal and gynecological infections, and as a preventive measure for surgical infections. It is widely used in clinical practice, offering notable advantages such as proven efficacy, broad antibacterial spectrum, high safety profile and low incidence of adverse reactions. Currently, the product has been listed in the National Essential Drug List (2018 edition) and Category B in the National Medical Insurance Drug List (2023 edition).

This approval will further solidify the Company's leading position in the anti-infective field. In the future, the Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 14 November 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.